11/20
08:13 am
howl
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference [Yahoo! Finance]
Low
Report
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference [Yahoo! Finance]
11/20
08:00 am
howl
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
Low
Report
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
11/19
08:20 am
howl
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Medium
Report
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
11/8
02:33 am
howl
Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.07 Nov. 08, 2024 2:25 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
Low
Report
Werewolf Therapeutics GAAP EPS of -$0.38 beats by $0.07 Nov. 08, 2024 2:25 AM ET By: Manshi Mamtora , CFA [Seeking Alpha]
11/7
09:02 am
howl
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Medium
Report
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
11/7
09:00 am
howl
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
10/31
08:00 am
howl
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
Medium
Report
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases
10/4
09:00 am
howl
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Low
Report
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
9/3
08:00 am
howl
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference